Last reviewed · How we verify
NCT04779957: RAIPONS
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
Phase 2 trial testing Tocilizumab in Kidney Transplantation in 18 participants. Completed in 9 August 2024.
9 August 2024
Quick facts
| Lead sponsor | University Hospital, Toulouse |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 1 October 2021 |
| Primary completion | 9 August 2024 |
| Estimated completion | 9 August 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Tocilizumab (tocilizumab) — full drug profile →
Conditions studied
- Kidney Transplantation — all drugs for Kidney Transplantation →
- Graft Failure — all drugs for Graft Failure →
Sponsor
University Hospital, Toulouse
Who can join
18 and older, any sex, with Kidney Transplantation or Graft Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Graft nephrectomy is associated with massive allo-sensitization following this event. The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Investigators propose here to evaluate in a phase II pilot study, the safety of the use of a single dose of Tocilizumab immediately before or after graft nephrectomy. The primary endpoint evaluated here is the occurrence of serious infectious complications following graft nephrectomy, with a treatment by Tocilizumab. Secondary endpoints evaluated here are - to evaluate all complications after graft nephrectomy, - and the Tocilizumab effectiveness to reduce anti-HLA antibodies at one year post nephrectomy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
IL-6 and diabetic kidney disease.
Zhang L, Xu F, Hou L. · · 2024 · cited 16× · PMID 39749325 · DOI 10.3389/fimmu.2024.1465625 -
Targeting IL-6 in antibody-mediated kidney transplant rejection.
Kanbay M, Mizrak B, Copur S, Alper EN, et al · · 2025 · cited 1× · PMID 40357502 · DOI 10.1093/ckj/sfaf108
Verify or expand the search:
- PubMed search for NCT04779957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tocilizumab
Trials testing the same drug.
- NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
- NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
- NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
Other recruiting trials for Kidney Transplantation
Currently open trials in the same condition.
- NCT07275632 — The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients · Phase 1, PHASE2 · recruiting
- NCT06568549 — Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective · Phase 4 · recruiting
- NCT06829719 — TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation · NA · recruiting
- NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
- NCT06886256 — Prehabilitation for Kidney Transplant Candidates · NA · recruiting
Other University Hospital, Toulouse trials
Trials by the same sponsor.
- NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
- NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
- NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
- NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
- NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04779957 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04779957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing